.svg)
The Nanotherm Product Suite
Nanotherm Therapeutics has developed an integrated suite of technologies to precisely treat solid tumors: The Nanotherm Therapy System (NTTS).
In Europe, NTTS is CE marked for the treatment of recurrent glioblastoma.
NanoTherm®
Bio-engineered non-toxic nanoparticles remain in place in tumor tissue due to their patented coating.
NanoPlan®
Software simulates therapy based on tumor size, location, and distribution of the nanoparticles.
NanoActivator™
RF energy heats the nanoparticles to either directly ablate tumor cells or enhance effectiveness of conventional therapy.
CONFIRM BEFORE TREATMENT
NanoTherm® deposits are easily seen on CT, allowing confirmation of the therapy prior to treatment.
01.
Deliver
02.
Confirm
03.
Plan
04.
Treat
Insensitive to motion
Uniquely, as implanted particles move with the tumor within the broad magnetic field, the heating area remains unaffected. With other external treatments, patient motion makes treatment challenging.
pipeline
Our current focus is resectable GBM and to explore collaborations for a new therapeutic indication.
01.
Resectable GBM
Goal: Target residual cancer cells along the resection cavity wall in resectable GBM.
Recurrent Glioblastoma ClinicalTrials.gov ID NCT06271421
Primary Glioblastoma: Randomized prospective clinical trial starting soon
02.
Solid tumors
Goal: Ablate unresectable solid tumors highly affected by patient movement
Lung, liver, and others
About Nanotherm Therapeutics Inc.
Patients with over 900 activations treated with NTTS
Years of experience
Active treatment
centers
Patents
ISO & MDR approved European manufacturer: MagForce NT GmbH has its quality management system which is ISO 13485:2016 certified, MDR EU QMS and MDR EU CE certified by DEKRA Certification B.V. (0344)